Vivos Therapeutics, Inc. VVOS
Set alert
0.11 USD 0.00 -0.79%
As of Nov 2, 12:42 PM ET
0.1125 Day range 0.1192
0.111 52-week range 2.72
- YTD
- -94.44%
- 1 year
- -95.62%
- Open
- 0.114
- Prev close
- 0.1138
- Mkt cap
- 3.79M
- Vol
- 367.42K
- Avg vol
- 15.04M
- EPS
- -1.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1125
- High
- 0.1192
- Forward P/E
- -9.31
- Beta
- 7.68
- Short ratio
- 0.66
- Inst. own
- 13.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 3.32
- 200-d avg
- 2.88
- 1y target
- 6.30
6M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 11, 2026 | 1 month ago |
| RSI: Oversold | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 24, 2026 | 2 months ago |
| RSI: Oversold | Aug 12, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| RSI: Oversold | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| RSI: Oversold | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 13, 2026 | 5 months ago |
| RSI: Oversold | May 7, 2026 | 5 months ago |
| RSI: Oversold | May 5, 2026 | 6 months ago |
Key statistics
- Market cap
- 24.76M
- Enterprise value
- 4.52M
- Trailing P/E
- 0.00
- Forward P/E
- -9.31
- PEG ratio
- 0.00
- Price / sales
- 1.77
- Price / book
- 22.86
- EPS (TTM)
- -4.99
- Beta
- 7.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -85.90%
- Revenue (TTM)
- 14.02M
- Revenue growth
- 19.40%
- Free cash flow
- -8.90M
- Total cash
- 6.90M
- Total debt
- 1.76M
- Return on equity
- -284.96%
- Shares outstanding
- 4.84M
- Short % of float
- 2.01%
- 50-day average
- 3.32
- 200-day average
- 2.88
Analyst view
Consensus: none
Price target (mean) 6.30 +5480.2% upside
Now 0.1129
- Target (low)
- 6.00
- Target (mean)
- 6.30
- Target (high)
- 6.60
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.43.
Financials — quick view
VVOS Revenue — quarterly 5.15M
VVOS Net income — quarterly -5.48M
VVOS EPS — quarterly -0.31
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.70 | -0.40 | +0.30 | +42.86% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.60 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.63 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -3.05 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Ascendiant Capital | reit | Buy | Buy |
| Nov 19, 2024 | Alliance Global Partners | main | Buy | Buy |
| Aug 20, 2024 | Ascendiant Capital | main | Buy | Buy |
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- vivos.com
News
- Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard
- Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
- Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M
- Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
- Vivos Therapeutics Announces Restructuring And Cost Reduction Plan With An Annual Savings Target Of $3.6M From Q4 2026
- Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on VVOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUNTSMAN RONALD KIRK | Chief Executive Officer | Purchase | Jun 19, 2023 | 1,826,520 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Strategic Wealth Investment Group, LLC | 2.07% | 100,000 | 512.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.60% | 28,802 | 147.47K | Sep 29, 2024 |
| OMERS Administration Corporation | 0.52% | 25,000 | 128.00K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.43% | 21,000 | 107.52K | Sep 29, 2024 |
| Sabby Management, LLC | 0.42% | 20,502 | 104.97K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.42% | 20,482 | 104.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.38% | 18,247 | 93.42K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.22% | 10,579 | 54.16K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 5,825 | 29.82K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 5,667 | 29.02K | Oct 30, 2024 |